Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas

Trends in Parasitology

Volumn 26, Issue 8, 2010, Pages 395-403

  Dujardin, Jean Claude ^a,b   González Pacanowska, Dolores ^b,c   Croft, Simon L ^b,d   Olesen, Ole F ^e   Späth, Gerald F ^b,f  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b The KALADRUG R consortium ^*  (Belgium)

^c INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e EUROPEAN COMMISSION   (Belgium)

^f CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BENZNIDAZOLE; EFLORNITHINE; FEXINIDAZOLE; MEGLUMINE ANTIMONATE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; PAROMOMYCIN; PENTAMIDINE; POSACONAZOLE; SITAMAQUINE; STIBOGLUCONATE SODIUM; SURAMIN; ANTIPROTOZOAL AGENT;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; CHEMOTHERAPY; CLINICAL TRIAL; DRUG RESEARCH; DRUG SAFETY; ENDEMIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; NONHUMAN; REVIEW; SINGLE DRUG DOSE; TRYPANOSOMATID INFECTION; VECTOR CONTROL; VISCERAL LEISHMANIASIS; ANIMAL; DEVELOPING COUNTRY; EUROPEAN UNION; INTERNATIONAL COOPERATION; LEISHMANIASIS, VISCERAL; RESEARCH; TRYPANOSOMIASIS, AFRICAN;

ANIMALS; ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; DEVELOPING COUNTRIES; ENDEMIC DISEASES; EUROPEAN UNION; HUMANS; INTERNATIONAL COOPERATION; LEISHMANIASIS, VISCERAL; RESEARCH; TRYPANOSOMIASIS, AFRICAN;

PROTOZOA; TRYPANOSOMATIDAE;

EID: 77955054226     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.04.012     Document Type: Review

References (70)

1. Stuart K., et al. Kinetoplastids: related protozoan pathogens, different diseases. J. Clin. Invest. 2008, 118:1301-1310.
2. Bern C., Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J. Med. Res. 2006, 123:275-288.
3. Fevre E.M., et al. Estimating the burden of rhodesiense sleeping sickness during an outbreak in Serere, eastern Uganda. BMC Public Health 2008, 8:96.
4. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis. 2001, 1:92-100.
5. Special Programme for Research and Training in Tropical Diseases, World Health Organization, WHO. (2005) Report of the Scientific Working Group on Chagas Disease, WHO.
6. Croft S.L., et al. Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 2006, 123:399-410.
7. Alvar J., et al. Chemotherapy in the treatment and control of leishmaniasis. Adv. Parasitol. 2006, 61:223-274.
8. Seifert K., et al. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int. J. Antimicrob. Agents 2003, 22:380-387.
9. Jhingran A., et al. Paromomycin: uptake and resistance in Leishmania donovani. Mol. Biochem. Parasitol. 2009, 164:111-117.
10. Berman J. Visceral leishmaniasis in the New World & Africa. Indian J. Med. Res. 2006, 123:289-294.
11. Priotto G., et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin. Infect. Dis. 2007, 45:1435-1442.
12. Barrett M.P., et al. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br. J. Pharmacol. 2007, 152:1155-1171.
13. Urbina J.A., Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 2003, 19:495-501.
14. Pinazo M.J., et al. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am. J. Trop. Med. Hyg. 2010, 82:583-587.
15. Urbina J.A., et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents 2003, 21:27-38.
16. Corrales M., et al. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob. Agents Chemother. 2005, 49:1556-1560.
17. Ausiello G., et al. Query3d: a new method for high-throughput analysis of functional residues in protein structures. BMC Bioinformatics 2005, 6:S5.
18. Lang T., et al. Bioluminescent Leishmania expressing luciferase for rapid and high throughput screening of drugs acting on amastigote-harbouring macrophages and for quantitative real-time monitoring of parasitism features in living mice. Cell. Microbiol. 2005, 7:383-392.
19. Thiberge S., et al. In vivo imaging of malaria parasites in the murine liver. Nat. Protoc. 2007, 2:1811-1818.
20. Amino R., et al. Imaging malaria sporozoites in the dermis of the mammalian host. Nat. Protoc. 2007, 2:1705-1712.
21. Wallace I.M., et al. M-Coffee: combining multiple sequence alignment methods with T-Coffee. Nucleic Acids Res. 2006, 34:1692-1699.
22. Morales M.A., et al. Phosphoproteome dynamics reveal heat-shock protein complexes specific to the Leishmania donovani infectious stage. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8381-8386.
23. Morales M.A., et al. Phosphoproteomic analysis of Leishmania donovani pro- and amastigote stages. Proteomics 2008, 8:350-363.
24. Alberola J., et al. Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis. Antimicrob. Agents Chemother. 2004, 48:641-643.
25. Guerrero E., et al. Role of positional hydrophobicity in the leishmanicidal activity of magainin 2. Antimicrob. Agents Chemother. 2004, 48:2980-2986.
26. Luque-Ortega J.R., et al. Identification of new leishmanicidal peptide lead structures by automated real-time monitoring of changes in intracellular ATP. Biochem. J. 2003, 375:221-230.
27. Mangoni M.L., et al. Temporins, small antimicrobial peptides with leishmanicidal activity. J. Biol. Chem. 2005, 280:984-990.
28. Ferraro E., et al. A novel structure-based encoding for machine-learning applied to the inference of SH3 domain specificity. Bioinformatics 2006, 22:2333-2339.
29. Zanzoni A., et al. Phospho3D: a database of three-dimensional structures of protein phosphorylation sites. Nucleic Acids Res. 2007, 35:D229-231.
30. Gray N.S., et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281:533-538.
31. Meijer L., Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res 2003, 36:417-425.
32. Reichwald C., et al. A new Heck reaction modification using ketone Mannich bases as enone precursors: parallel synthesis of anti-leishmanial chalcones. Bioorg. Med. Chem. Lett. 2008, 18:1985-1989.
33. Garnier T., et al. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J. Antimicrob. Chemother. 2007, 60:802-810.
34. Gros L., et al. Evaluation of azasterols as anti-parasitics. J. Med. Chem. 2006, 49:6094-6103.
35. Grant K.M., et al. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob. Agents Chemother. 2004, 48:3033-3042.
36. Luque-Ortega J.R., et al. In vivo monitoring of intracellular ATP levels in Leishmania donovani promastigotes as a rapid method to screen drugs targeting bioenergetic metabolism. Antimicrob. Agents Chemother. 2001, 45:1121-1125.
37. Morales M.A., et al. Over-expression of Leishmania major MAP kinases reveals stage-specific induction of phosphotransferase activity. Int. J. Parasitol. 2007, 37:1187-1199.
38. Morales M.A., et al. Leishmania major MPK7 protein kinase activity inhibits intracellular growth of the pathogenic amastigote stage. Eukaryot. Cell 2010, 9:22-30.
39. Barak E., et al. Differentiation of Leishmania donovani in host-free system: analysis of signal perception and response. Mol. Biochem. Parasitol. 2005, 141:99-108.
40. Boitz J.M., Ullman B. A conditional mutant deficient in hypoxanthine-guanine phosphoribosyltransferase and xanthine phosphoribosyltransferase validates the purine salvage pathway of Leishmania donovani. J. Biol. Chem. 2006, 281:16084-16089.
41. Carter N.S., et al. Purine and pyrimidine metabolism in Leishmania. Adv. Exp. Med. Biol. 2008, 625:141-154.
42. Arakaki T.L., et al. Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol. Microbiol. 2008, 68:37-50.
43. Harkiolaki M., et al. The crystal structure of Trypanosoma cruzi dUTPase reveals a novel dUTP/dUDP binding fold. Structure 2004, 12:41-53.
44. Bernier-Villamor V., et al. Characterization of deoxyuridine 5'-triphosphate nucleotidohydrolase from Trypanosoma cruzi. FEBS Lett. 2002, 526:147-150.
45. Hidalgo-Zarco F., et al. Kinetic properties and inhibition of the dimeric dUTPase-dUDPase from Leishmania major. Protein Sci. 2001, 10:1426-1433.
46. Moroz O.V., et al. The crystal structure of a complex of Campylobacter jejuni dUTPase with substrate analogue sheds light on the mechanism and suggests the " basic module" for dimeric d(C/U)TPases. J. Mol. Biol. 2004, 342:1583-1597.
47. Moroz O.V., et al. Dimeric dUTPases, HisE, and MazG belong to a new superfamily of all-alpha NTP pyrophosphohydrolases with potential " house-cleaning" functions. J. Mol. Biol. 2005, 347:243-255.
48. Whittingham J.L., et al. dUTPase as a platform for antimalarial drug design: structural basis for the selectivity of a class of nucleoside inhibitors. Structure 2005, 13:329-338.
49. Pena-Diaz J., et al. Mitochondrial localization of the mevalonate pathway enzyme 3-Hydroxy-3-methyl-glutaryl-CoA reductase in the Trypanosomatidae. Mol. Biol. Cell 2004, 15:1356-1363.
50. Parodi-Talice A., et al. Proteomic analysis of metacyclic trypomastigotes undergoing Trypanosoma cruzi metacyclogenesis. J. Mass Spectrom. 2007, 42:1422-1432.
51. Nguyen C., et al. Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J. Med. Chem. 2006, 49:4183-4195.
52. Cammerer S.B., et al. Quinuclidine derivatives as potential antiparasitics. Antimicrob. Agents Chemother. 2007, 51:4049-4061.
53. Johansson N.G., Eriksson S. Structure-activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. Acta Biochim. Pol. 1996, 43:143-160.
54. Baliani A., et al. Design and synthesis of a series of melamine-based nitroheterocycles with activity against trypanosomatid parasites. J. Med. Chem. 2005, 48:5570-5579.
55. Nguyen C., et al. Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target. J. Med. Chem. 2005, 48:5942-5954.
56. Augustine J.K., et al. An unusual reaction of benzalaminoacetals in trifluoroacetic acid: facile synthesis of 2-benzylpyrazines. J. Org. Chem. 2008, 73:1176-1179.
57. McCarthy O., et al. Design, synthesis and evaluation of novel uracil acetamide derivatives as potential inhibitors of Plasmodium falciparum dUTP nucleotidohydrolase. Eur. J. Med. Chem. 2009, 44:678-688.
58. Vidal A.E., et al. Crystal structure and DNA repair activities of the AP endonuclease from Leishmania major. J. Mol. Biol. 2007, 373:827-838.
59. Turkenburg J.P., et al. Structure of a pullulanase from Bacillus acidopullulyticus. Proteins 2009, 76:516-519.
60. Sundar S., Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin. Investig. Drugs 2008, 17:787-794.
61. Boelaert M., et al. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop. Med. Int. Health 2009, 14:639-644.
62. Maes L., et al. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrob. Agents Chemother. 2004, 48:2056-2060.
63. Mookerjee Basu J., et al. Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection. Antimicrob. Agents Chemother. 2008, 52:1080-1093.
64. Rijal S., et al. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?. Microbes Infect. 2007, 9:529-535.
65. Kumar D., et al. In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob. Agents Chemother. 2009, 53:835-838.
66. Peacock C.S., et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 2007, 39:839-847.
67. Dujardin J.C. Structure, dynamics and function of Leishmania genome: resolving the puzzle of infection, genetics and evolution?. Infect. Genet. Evol. 2009, 9:290-297.
68. Croft S.L., et al. Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol. 2003, 126:165-172.
69. Alam M.Z., et al. Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect. Genet. Evol. 2009, 9:24-31.
70. Eichner M., et al. Antiviral prophylaxis during pandemic influenza may increase drug resistance. BMC Infect. Dis. 2009, 9:4.